Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PURPOSE: Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily. A microencapsulated long-acting formulation (LAR) of octreotide acetate has been developed for once-monthly intramuscular dosing. PATIENTS AND METHODS: A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome. Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population. RESULTS: Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P ≥ .72 for all pairwise comparisons). Control of stool frequency was similar in all treatment groups. Flushing episodes were best controlled in the 20-mg LAR and SC groups; the 10-mg LAR treatment was least effective in the control of flushing. Treatment was well tolerated by patients in all four groups. CONCLUSION: Once octreotide steady-state concentrations are achieved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SC octreotide. A starting dose of 20 mg of octreotide LAR is recommended. Supplemental SC octreotide is needed for approximately 2 weeks after initiation of octreotide LAR treatment. Occasional rescue SC injections may be required for possibly 2 to 3 months until steady-state octreotide levels from the LAR formulation are achieved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An analysis of 8305 cases of carcinoid tumors
Modlin, I. M., & Sandor, A. (2000) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2 · Cited by 1,200
Carcinoid TumorsAn analysis of 2837 cases
Godwin, J. D. (1975) · Cancer · doi:10.1002/1097-0142(197508)36:2<560::aid-cncr2820360235>3.0.co;2-4 · Cited by 1,106
Treatment of the Malignant Carcinoid Syndrome
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., & Hahn, R. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151102 · Cited by 849
Self-citationGorden, P., Comi, R. J., Maton, P. N., & Go, V. L. W. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-1-35 · Cited by 258
Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patients
Lancranjan, I., Bruns, C., Grass, P. N., Jaquet, P., Jervell, J., Kendall-Taylor, P., Lamberts, S. W. J., Marbach, P., Ørskov, H., Pagani, G. A., et al. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90087-6 · Cited by 145
The epidemiology of carcinoid tumours in England and Scotland
Newton, J. N., Swerdlow, A. J., Silva, I. D. S., Vessey, M., Grahame‐Smith, D., Primatesta, P., & Reynolds, D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.424 · Cited by 102
Lancranjan, I., Bruns, C., Grass, P. N., Jaquet, P., Jervell, J., Kendall-Taylor, P., Lamberts, S. W. J., Marbach, P., Ørskov, H., Pagani, G. A., et al. (1995) · Metabolism · doi:10.1016/0026-0495(95)90306-2 · Cited by 90
Metastatic Carcinoid Tumors and the Malignant Carcinoid Syndrome
Kvols, L. K. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb17296.x · Cited by 79
Janmohamed, S., & Bloom, S. R. (1997) · Postgraduate Medical Journal · doi:10.1136/pgmj.73.858.207 · Cited by 18
Cited by
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Current Status of Gastrointestinal Carcinoids
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., & Shapiro, M. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.038 · Cited by 848
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea
Benson, A. B., Ajani, J. A., Catalano, R. B., Engelking, C., Kornblau, S. M., Martenson, J. A., McCallum, R., Mitchell, E. P., O'Dorisio, T. M., Vokes, E. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.132 · Cited by 631
Self-citationGastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Endocrine tumours of the pancreas
Öberg, K., & Eriksson, B. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.06.002 · Cited by 543
Boudreaux, J. P., Klimstra, D. S., Hassan, M. M., Woltering, E. A., Jensen, R. T., Goldsmith, S. J., Nutting, C., Bushnell, D. L., Caplin, M. E., & Yao, J. C. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb2a5 · Cited by 539
Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours
Plöckinger, U., Rindi, G., Arnold, R., Eriksson, B., Krenning, E. P., de Herder, W. W., Goede, A., Caplin, M., Öberg, K., Reubi, J. C., et al. (2004) · Neuroendocrinology · doi:10.1159/000085237 · Cited by 477
MODLIN, I. M., PAVEL, M., KIDD, M., & GUSTAFSSON, B. I. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04174.x · Cited by 410
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study
Halperin, D. M., Shen, C., Dasari, A., Xu, Y., Chu, Y., Zhou, S., Shih, Y.-C. T., & Yao, J. C. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30110-9 · Cited by 390
Strosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Self-citationGuidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours
Ramage, J. K., Davies, A. H. G., Ardill, J., Bax, N., Caplin, M., Grossman, A., Hawkins, R., McNicol, A. M., Reed, N., Sutton, R., et al. (2005) · Gut · doi:10.1136/gut.2004.053314 · Cited by 350
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome
Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., Welin, S., Warner, R. R. P., Lombard-Bohas, C., Kunz, P. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2780 · Cited by 303
Self-citationFactors Associated with Progression of Carcinoid Heart Disease
Møller, J. E., Connolly, H. M., Rubin, J., Seward, J. B., Modesto, K., & Pellikka, P. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021451 · Cited by 298
Self-citationPrognosis of Carcinoid Heart Disease: Analysis of 200 Cases Over Two Decades
Møller, J. E., Pellikka, P. A., Bernheim, A. M., Schaff, H. V., Rubin, J., & Connolly, H. M. (2005) · Circulation · doi:10.1161/circulationaha.105.553750 · Cited by 278
Self-citationAnthony, L. B., Strosberg, J. R., Klimstra, D. S., Maples, W. J., O'Dorisio, T. M., Warner, R. R. P., Wiseman, G. A., Benson, A. B., & Pommier, R. F. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ec1261 · Cited by 276
Self-citationSomatostatin Analogs in Clinical Practice: A Review
Gomes-Porras, M., Cárdenas-Salas, J., & Álvarez-Escolá, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051682 · Cited by 264
Resistance to Somatostatin Analogs in Acromegaly
Colao, A., Auriemma, R. S., Lombardi, G., & Pivonello, R. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0002 · Cited by 257
Eriksson, B., Klöppel, G., Krenning, E., Ahlman, H., Plöckinger, U., Wiedenmann, B., Arnold, R., Auernhammer, C., Körner, M., Rindi, G., et al. (2008) · Neuroendocrinology · doi:10.1159/000111034 · Cited by 254
Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H.-J., Lupp, A., Korbonits, M., Castaño, J. P., Wester, H.-J., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 253
Carcinoid syndrome: diagnosis and medical management
van der Lely, A. J., & Herder, W. W. D. (2005) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302005000500028 · Cited by 73
Metadata
- Authors
- Rubin, J., Ajani, J., Schirmer, W., Venook, A. P., Bukowski, R., Pommier, R., Saltz, L., Dandona, P., & Anthony, L.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-02
- Volume
- 17
- Issue
- 2
- Pages
- 600-600
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1898402948
- Cited by
- 389
- References
- 9
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.